Home Ingredients EstroG-100® (Three-Herb Menopause Extract — Naturalendo Tech)
Menopause SupportWomen's Health

EstroG-100® (Three-Herb Menopause Extract — Naturalendo Tech)

Cynanchum wilfordii / Phlomis umbrosa / Angelica gigas
Evidence Level
Moderate
3 Clinical Trials
6 Documented Benefits
3/5 Evidence Score

EstroG-100® is a standardized blend of root extracts from three herbs used in Korean traditional medicine: Cynanchum wilfordii, Phlomis umbrosa and Angelica gigas. It is made by Naturalendo Tech in South Korea. In a 12-week placebo-controlled trial in 64 women before, during and after menopause, it lowered Kupperman Menopause Index scores (from 29.5 to 11.3, versus 29.2 to 23.7 on placebo) and improved hot flushes, sleep, nervousness, low mood, fatigue and vaginal dryness. A second 12-week trial in Iran reported fewer hot flashes from week 6, though only 70 of 120 women were analyzed. EFSA judged the blend safe in supplements only up to 175 mg a day, about a third of the 514 mg used in the first trial, because of liver and blood changes in rat studies. Lab tests found no estrogen activity, but people with estrogen-sensitive conditions should ask their doctor first.

Studied Dose 514 mg/day for 12 weeks in the main US trial (dose per the EFSA review of that trial); 514 mg with 50 mg GABA in a 5-week trial; two capsules daily for 12 weeks in Iran. EFSA judged the blend safe in supplements only up to 175 mg/day for postmenopausal women.
Active Compound Standardized root extracts of Cynanchum wilfordii, Phlomis umbrosa and Angelica gigas.

Benefits

Hot flash and night sweat reduction

In a 12-week placebo-controlled trial in 64 women, the vasomotor items of the Kupperman index (hot flushes and sweating) improved more with EstroG-100 than with placebo. A second 12-week trial in postmenopausal women reported fewer mild, moderate and severe hot flashes than placebo by week 6, though only 70 of 120 randomized women were analyzed.

Supported by Trial 2, Trial 1

Overall menopausal symptom scores

In the 64-woman trial, the Kupperman Menopause Index fell from 29.5 to 11.3 with EstroG-100 versus 29.2 to 23.7 with placebo over 12 weeks (p<0.01), with improvements in tingling, dizziness, fatigue and joint aches as well as hot flushes.

Supported by Trial 1

Sleep during menopause

Insomnia scores on the Kupperman index improved more with EstroG-100 than with placebo in the 12-week trial. In a 5-week trial of EstroG-100 combined with GABA, sleep quality also improved, but that result cannot be credited to EstroG-100 alone.

Supported by Trial 3, Trial 1

Vaginal dryness relief

Vaginal dryness, a primary outcome of the 64-woman trial, improved significantly more with EstroG-100 than with placebo over 12 weeks (p<0.05). This has not yet been confirmed in a second trial.

Supported by Trial 1

Nervousness and low mood during menopause

Nervousness and melancholia items of the Kupperman index improved more with EstroG-100 than with placebo in the 12-week trial. The EstroG-100 plus GABA trial also reported less tension and fewer depressive feelings.

Supported by Trial 3, Trial 1

No estrogen activity in laboratory tests

In laboratory tests, the three-herb extract did not activate estrogen receptors alpha or beta, did not stimulate MCF-7 breast cancer cell growth, and did not increase uterine weight in ovariectomized rats. These are laboratory and animal findings only and do not show safety for people with estrogen-sensitive conditions.

Supported by Trial 1

Mechanism of action

1

No estrogen receptor activation (laboratory)

The EstroG-100 extract showed no estrogenic activity in receptor and breast cell tests and did not raise uterine weight in ovariectomized rats.

2

Mechanism in people not established

How the blend eases menopausal symptoms has not been shown. Proposed explanations involving brain neurotransmitters or stress hormones have not been tested in published human studies.

Clinical trials

1
EstroG-100 for Menopausal Symptoms in US Women
PubMed

Randomized, double-blind, placebo-controlled trial of EstroG-100 for 12 weeks; the EFSA review of this trial gives the dose as 514 mg/day (Chang et al. 2012, Phytother Res)

64 women before, during and after menopause (31 EstroG-100, 33 placebo); White Hispanic, White non-Hispanic and African American.

Kupperman Menopause Index fell from 29.5 to 11.3 with EstroG-100 versus 29.2 to 23.7 with placebo (p<0.01). Vasomotor, tingling, insomnia, nervousness, melancholia, dizziness, fatigue and joint pain items, and vaginal dryness, improved versus placebo (p<0.05). No weight gain or serious side effects.

2
EstroG-100 for Hot Flashes in Postmenopausal Women
PubMed

Randomized, double-blind, placebo-controlled trial of two EstroG-100 capsules daily for 12 weeks (Farzaneh et al. 2024, Explore (NY))

120 postmenopausal women with hot flashes randomized; 35 per group analyzed.

At week 3, only moderate hot flashes differed (fewer with EstroG-100, p=0.004). By week 6, mild, moderate and severe hot flashes were all less frequent than with placebo (p<0.001). Heavy dropout limits confidence.

3
EstroG-100 Plus GABA for Menopausal Symptoms
PubMed

Randomized, double-blind, placebo-controlled trial of EstroG-100 514 mg plus GABA 50 mg, as needed in week 1 then daily through week 5 (Snigdha et al. 2025, Menopause)

80 healthy women in menopause (mean age about 53).

Hot flash intensity and number fell versus placebo from days 1 and 2; stress, mood swings, headaches, sleep quality, depressive feelings, tension and sexual function also improved. Because GABA was included, effects cannot be credited to EstroG-100 alone. Three authors were employees of OLLY PBC, maker of the Mellow Menopause supplement.

Side effects and drug interactions

Common Potential side effects

No serious side effects or weight gain were reported in the 12-week trials.
EFSA judged the blend safe in supplements only up to 175 mg/day for postmenopausal women, about a third of the 514 mg/day used in the 12-week US trial, because 28- and 90-day rat studies showed dose-related rises in liver weight, albumin and total protein, plus red blood cell changes. EFSA said 12 weeks of normal human liver and blood tests were not enough to dismiss the concern.
Two of the three roots, Angelica gigas and Cynanchum wilfordii, each raised liver weight and blood protein levels with dose when tested alone in 90-day rat studies reviewed by EFSA.
Cynanchum wilfordii is hard to tell apart from the related Cynanchum auriculatum, and substitution in herbal markets has been reported, so buy products that verify plant species.
Lack of estrogen activity in laboratory tests does not guarantee safety for people with estrogen-sensitive conditions; ask your doctor first.
Pregnancy and breastfeeding: safety has not been studied; ask your doctor first.

Important Drug interactions

Tamoxifen and aromatase inhibitors: safety of combined use has not been studied; ask your oncologist before use.
Hormone therapy: combined use has not been studied; ask your doctor.
Medicines that can affect the liver: rat studies of the blend showed liver changes, so ask your doctor before combining.
No drug interaction studies have been published.

Featured in these supplement guides

Menopause Symptoms→

More Menopause Support Ingredients

Menopause Support
Black Cohosh (Actaea racemosa)
Black cohosh is a North American plant in the buttercup family and one of the most frequen…
Menopause Support
Shatavari (Asparagus racemosus / Xeya®)
Shatavari is the root of Asparagus racemosus, an herb used in Ayurveda for women's health.…
Menopause Support
FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives)
FenuSmart (also written FenuSMART) is Akay's standardized fenugreek (Trigonella foenum-gra…
Menopause Support
Lifenol™ (Standardized Hop Extract for Menopause — Givaudan)
Lifenol is Givaudan's extract of female hop flowers (Humulus lupulus) standardized to 8-pr…

Explore Other Ingredients

Sleep Health
Melatonin
Melatonin is a hormone made by the pineal gland that signals biological darkness and helps…
Sleep Health
Valerian Root
Valerian root (Valeriana officinalis) is a traditional herb taken for relaxation and occas…
Metabolic Health
Magnesium
Magnesium is an essential mineral and a cofactor in more than 300 enzyme systems, includin…

Frequently asked questions about EstroG-100® (Three-Herb Menopause Extract — Naturalendo Tech)

What is in EstroG-100?

EstroG-100 is a hot-water extract of three roots used in Korean traditional medicine: Cynanchum wilfordii, Phlomis umbrosa and Angelica gigas. It is made by Naturalendo Tech in South Korea. Trial results describe the blend as a whole, so no one can say which root, if any, drives the effects.

How much EstroG-100 has been studied, and how much is considered safe?

The main 12-week US trial used 514 mg a day, according to the EFSA review of that trial, and a 5-week trial paired 514 mg with 50 mg of GABA. EFSA judged the blend safe in food supplements only up to 175 mg a day for postmenopausal women, because rat studies showed liver and blood changes. Check the label and ask your doctor about the right amount for you.

Does EstroG-100 act like estrogen?

In laboratory tests, the blend did not activate estrogen receptors alpha or beta, did not stimulate MCF-7 breast cancer cell growth and did not raise uterine weight in ovariectomized rats. These are laboratory and animal results only, so people with estrogen-sensitive conditions, or who take tamoxifen or aromatase inhibitors, should ask their doctor first.

How soon did women notice changes in the trials?

In the Iranian trial, only moderate hot flashes differed from placebo at week 3, and mild, moderate and severe hot flashes were all less frequent by week 6. In the 5-week trial of the blend with GABA, hot flash intensity and number fell versus placebo within the first two days, but that product also contained GABA, so the timing cannot be credited to EstroG-100 alone.

What is EstroG-100?

EstroG-100® is a standardized blend of root extracts from three herbs used in Korean traditional medicine: Cynanchum wilfordii, Phlomis umbrosa and Angelica gigas. It is made by Naturalendo Tech in South Korea.

What is EstroG-100 used for?

EstroG-100 is researched primarily for Menopause Support and Women's Health. In a 12-week placebo-controlled trial in 64 women, the vasomotor items of the Kupperman index (hot flushes and sweating) improved more with EstroG-100 than with placebo.

What is the recommended dosage of EstroG-100?

The clinically studied dose is 514 mg/day for 12 weeks in the main US trial (dose per the EFSA review of that trial); 514 mg with 50 mg GABA in a 5-week trial; two capsules daily for 12 weeks in Iran. EFSA judged the blend safe in supplements only up to 175 mg/day for postmenopausal women. Always follow the product label and check with a healthcare provider for personal advice.

Is EstroG-100 safe, and does it have side effects?

Side effects and cautions reported for EstroG-100 include: No serious side effects or weight gain were reported in the 12-week trials. EFSA judged the blend safe in supplements only up to 175 mg/day for postmenopausal women, about a third of the 514 mg/day used in the 12-week US trial, because 28- and 90-day rat studies showed dose-relat… It may also interact with some medications. EstroG-100 is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does EstroG-100 interact with any medications?

Possible interactions include: Tamoxifen and aromatase inhibitors: safety of combined use has not been studied; ask your oncologist before use. Hormone therapy: combined use has not been studied; ask your doctor. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for EstroG-100?

NutraSmarts rates the evidence for EstroG-100 as Moderate (3 out of 5). It is backed by 3 study summaries and 6 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(6 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Chang A, Kwak BY, Yi K, Kim JS. The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study. Phytother Res. 2012;26(4):510-6. doi: 10.1002/ptr.3597.PubMedUsed to support: 12-week RCT in 64 women before, during and after menopause: Kupperman Menopause Index fell from 29.5 to 11.3 with EstroG-100 versus 29.2 to 23.7 with placebo, and vasomotor, insomnia, nervousness, melancholia, fatigue, joint pain and vaginal dryness scores improved versus placebo, without weight gain or serious side effects.
  2. Kim SJ, Jin SW, Lee GH, Kim YA, Jeong HG. Evaluation of Estrogenic Activity of Extract from the Herbal Mixture Cynanchum wilfordii Hemsley, Phlomis umbrosa Turczaninow, and Angelica gigas Nakai. Toxicol Res. 2017;33(1):71-77. doi: 10.5487/TR.2017.33.1.071.PubMedUsed to support: Laboratory and rat study of the three-herb extract: no estrogenic activity in estrogen receptor cell tests, no selective activity at estrogen receptors alpha or beta, no increase in MCF-7 breast cancer cell growth and no uterine weight gain in ovariectomized rats. Not a human study.
  3. Farzaneh F, Fallah G, Khalili-Chelik A, Fallah A, Hosseini M. Estro G-100 herbal extract and hot flashes in postmenopausal women: A randomized double-blinded controlled trial. Explore (NY). 2024;20(3):334-339. doi: 10.1016/j.explore.2023.09.004.PubMedUsed to support: 12-week RCT in postmenopausal women with hot flashes (120 randomized, 35 per group analyzed): fewer mild, moderate and severe hot flashes than placebo by week 6. Heavy dropout.
  4. Snigdha S, Lau E, Ademola J, Frost R, Patel P. Effect of a novel nutraceutical combination of EstroG-100 and γ-aminobutyric acid (GABA) in attenuating symptoms of menopause in healthy adult women: a randomized double-blinded placebo-controlled study. Menopause. 2025;32(11):1036-1045. doi: 10.1097/GME.0000000000002608.PubMedUsed to support: 5-week RCT in 80 women of EstroG-100 514 mg plus GABA 50 mg: hot flash intensity and number, stress, mood, sleep and sexual function improved versus placebo. The combination design means effects cannot be credited to EstroG-100 alone; three authors were employees of OLLY PBC, maker of the Mellow Menopause supplement.
  5. Kim Y, Choi H, Shin J, Jo A, Lee KE, Cho SS, Hwang YP, Choi C. Molecular Discrimination of Cynanchum wilfordii and Cynanchum auriculatum by InDel Markers of Chloroplast DNA. Molecules. 2018;23(6):1337. doi: 10.3390/molecules23061337.PubMedUsed to support: Explains that Cynanchum wilfordii roots are hard to tell apart from Cynanchum auriculatum and presents DNA markers to identify them and reduce adulteration in commercial markets. Supports the species-authentication caution.
  6. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), Turck D, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuhäuser-Berthold M, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjödin A, Stern M, Tomé D, Vinceti M, Willatts P, Engel KH, Marchelli R, Pöting A, Poulsen M, Schlatter JR, Turla E, van Loveren H. Statement on the safety of EstroG-100™ as a novel food pursuant to Regulation (EC) No 258/97. EFSA J. 2017;15(5):e04778. doi: 10.2903/j.efsa.2017.4778.PubMedUsed to support: European Food Safety Authority statement on EstroG-100, a hot-water extract of Cynanchum wilfordii, Phlomis umbrosa and Angelica gigas roots: reconfirmed it as safe in food supplements only up to 175 mg/day for postmenopausal women, below the 514 mg/day proposed by the applicant and used in the 12-week Chang 2012 trial. The limit rests on dose-related liver-weight, albumin and total-protein increases and red blood cell changes in 28- and 90-day rat studies of the blend, with similar liver findings for Angelica gigas and Cynanchum wilfordii tested alone; EFSA said 12 weeks of human liver and blood data were not enough to dismiss the concern.